Prime Medicine, Inc. PRME
We are a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Our approach is grounded in Prime Editing, a next-generation gene editing technology that enables targeted modifications to genomic DNA without introducing double-stranded breaks. We believe Prime Editing represents the most versatile and precise method for rewriting, replacing, or repairing DNA sequences and may allow us to address a broad spectrum of diseases with an improved safety and specificity profile relative to earlier editing technologies. We are advancing a pipeline of wholly owned in vivo programs targeting diseases of the liver, Cystic Fibrosis, or CF, programs with the support of the Cystic Fibrosis Foundation, or CFF, and partnered ex vivo programs with Bristol-Myers Squibb, or BMS, supported by our modular delivery and Prime Editor platform. Early clinical data from our ex vivo program, PM359 for CGD, have demonstrated restoration of functional protein activity in treated patients, providing clinical validation of Prime Editing and a potentially curative treatment for CGD patients.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $4.6M | $3.0M | $0 | $0 | $0 | $5.2M | — |
| R&D | $160.6M | $155.3M | $147.9M | $86.7M | $70.5M | $3.0M | — |
| SG&A | $52.3M | $50.2M | $43.4M | $29.8M | $13.9M | $3.2M | — |
| Total operating expenses | $213.0M | $205.4M | $204.8M | $116.5M | $84.5M | $6.1M | — |
| Operating income | -$208.3M | -$202.5M | -$204.8M | -$116.5M | -$84.5M | -$932.0K | — |
| Pre-tax income | -$201.1M | -$195.9M | -$197.9M | -$120.9M | -$164.9M | -$1.5M | — |
| Income tax | $0 | $0 | $279.0K | $948.0K | $486.0K | $1.9M | — |
| Net income | -$201.1M | -$195.9M | -$198.1M | -$121.8M | -$165.4M | -$3.4M | — |
| EPS, basic | -1.35 | -1.65 | -2.18 | -4.19 | -14.19 | -1.91 | — |
| EPS, diluted | -1.35 | -1.65 | -2.18 | -4.19 | -14.19 | -1.91 | — |
| Shares, diluted (wtd. avg.) | 148.8M | 118.6M | 91.0M | 33.9M | 13.0M | 2.6M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $63.0M | $182.5M | $55.1M | $201.1M | $198.5M | $37.0M | $8.6M |
| Short-term investments | — | — | — | $98.5M | $68.2M | — | — |
| Total current assets | $181.3M | $211.9M | $143.0M | $296.6M | $270.6M | — | — |
| Property, plant and equipment | $20.6M | $24.4M | $22.7M | $19.0M | $4.9M | — | — |
| Total assets | $342.7M | $297.5M | $193.9M | $360.3M | $301.9M | — | — |
| Accounts payable | $8.9M | $11.4M | $19.5M | $4.3M | $1.4M | — | — |
| Total current liabilities | $37.4M | $38.0M | $56.4M | $26.7M | $58.0M | — | — |
| Total liabilities | $221.9M | $144.4M | $60.8M | $44.0M | $62.3M | — | — |
| Retained earnings | -$888.4M | -$687.2M | -$491.3M | -$293.2M | -$171.4M | — | — |
| Total equity | $120.9M | $153.1M | $133.1M | $316.3M | -$156.2M | $2.3M | -$2.6M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$162.6M | -$122.9M | -$165.4M | -$131.8M | -$34.1M | -$5.5M | — |
| Depreciation and amortisation | $7.3M | $6.1M | $4.7M | $2.2M | $568.0K | $43.0K | — |
| Stock-based compensation | $29.3M | $26.1M | $13.9M | $6.5M | $1.7M | $391.0K | — |
| Capital expenditure | $4.5M | $7.3M | $8.7M | $16.1M | $4.2M | $639.0K | — |
| Investing cash flow | -$108.8M | $68.5M | $18.7M | -$47.1M | -$73.6M | -$1.1M | — |
| Financing cash flow | $151.5M | $195.9M | $655.0K | $181.5M | $269.3M | $34.9M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001628280-26-013569.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | $5.2M | $0 | $0 | $0 | $3.0M | $4.6M |
| Gross profit | — | — | — | — | — | — | — |
| Net income | — | -$3.4M | -$165.4M | -$121.8M | -$198.1M | -$195.9M | -$201.1M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced Item 2.02
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Regulation FD disclosure Item 7.01
- Results announced Item 2.02
- Regulation FD disclosure Item 7.01
- Results announced Item 2.02
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2836
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AMGN | AMGEN INC | $237.48B | 30.9x | 10.0% |
| GILD | GILEAD SCIENCES, INC. | $193.48B | 23.0x | 2.4% |
| MRNA | Moderna, Inc. | $79.89B | — | -39.9% |
| RVMD | Revolution Medicines, Inc. | $40.08B | — | — |
| BIIB | BIOGEN INC. | $37.01B | 28.5x | 2.2% |
| EXEL | EXELIXIS, INC. | $15.99B | 23.2x | 7.0% |
| NBIX | NEUROCRINE BIOSCIENCES INC | $14.51B | 30.6x | 21.4% |
| HALO | HALOZYME THERAPEUTICS, INC. | $14.26B | 49.1x | 37.6% |